Proteomics analysis in lung cancer: Challenges and opportunities

Respirology

Volumn 12, Issue 1, 2007, Pages 22-28

  Kikuchi, Takefumi ^a   Carbone, David P ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Fingerprint; Lung tumour; Proteomics

Indexed keywords

BIOLOGICAL MARKER; DNA;

BIOINFORMATICS; CANCER CLASSIFICATION; DISEASE MARKER; DNA MICROARRAY; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL INSTRUMENTATION; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS;

HUMANS; LUNG NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 33845720356     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.00957.x     Document Type: Review

References (45)

1. Edwards BK, Brown ML, Wingo PA et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl. Cancer Inst. 2005; 97: 1407-27.
2. Ries L, Harkins D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2003, based on November 2005 SEER data submission, posted to the SEER web site, 2006 edition. National Cancer Institute, Bethesda, MD, 2003.
3. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-7.
4. Garber ME, Troyanskaya OG, Schluens K et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA 2001; 98: 13784-9.
5. Beer DG, Kardia SL, Huang CC et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 2002; 8: 816-24.
6. Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 2001; 98: 13790-5.
7. Wright GL Jr. Two-dimensional acrylamide gel electrophoresis of cancer-patient serum proteins. Ann. Clin. Lab. Sci. 1974; 4: 281-93.
8. Hirano T, Franzen B, Uryu K et al. Detection of polypeptides associated with the histopathological differentiation of primary lung carcinoma. Br. J. Cancer 1995; 72: 840-8,.
9. Bergman AC, Benjamin T, Alaiya A et al. Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 2000; 21: 679-86.
10. Oh JM, Brichory F, Puravs E et al. A database of protein expression in lung cancer. Proteomics 2001; 1: 1303-19.
11. Chen G, Gharib TG, Huang CC et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin. Cancer Res. 2002; 8: 2298-305.
12. Gharib TG, Chen G, Wang H et al. Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 2002; 4: 440-8.
13. Chen G, Gharib TG, Wang H et al. Protein profiles associated with survival in lung adenocarcinoma. Proc. Natl. Acad. Sci. USA 2003; 100: 13537-42.
14. Omenn GS, States DJ, Adamski M et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005; 5: 3226-45.
15. Amann JM, Chaurand P, Gonzalez AL et al. Selective profiling of proteins in lung cancer cells from fine needle aspirates by MALDI-TOF mass spectrometry. Clin. Cancer Res. 2006; 12: 5142-50.
16. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med. 2001; 7: 493-6.
17. Caprioli RM. Deciphering protein molecular signatures in cancer tissues to aid in diagnosis, prognosis, and therapy. Cancer Res. 2005; 65: 10642-5.
18. Chaurand P, Sanders ME, Jensen RA, Caprioli RM. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am. J. Pathol. 2004; 165: 1057-68.
19. Yanagisawa K, Shyr Y, Xu BJ et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003; 362: 433-9.
20. Kikuchi T, Massion PP, Shyr Y et al. Proteomic analysis of lung cancer tumors. J. Clin. Oncol. 2006; 24: 371S.
21. Petricoin, EF 3rd, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst. 2002; 94: 1576-8.
22. Adam BL, Qu Y, Davis JW et al. Serum protein finger-printing coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002; 62: 3609-14.
23. Mian S, Ball G, Hornbuckle J et al. A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions. Proteomics 2003; 3: 1725-37.
24. Yang SY, Xiao XY, Zhang WG et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005; 5: 83.
25. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003; 40: 267-79.
26. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291: 1304-51.
27. Washburn MP, Wolters D, Yates JR 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 2001; 19: 242-7.
28. Chen EI, Hewel J, Felding-Habermann B, Yates JR 3rd. Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT). Mol. Cell Proteomics 2006; 5: 53-6.
29. Jessani N, Niessen S, Wei BQ et al. A streamlined platform for high-content functional proteomics of primary human specimens. Nat. Methods 2005; 2: 691-7.
30. Kislinger T, Cox B, Kannan A et al. Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 2006; 125: 173-86.
31. Mauri P, Scarpa A, Nascimbeni AC et al. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J. 2005; 19: 1125-7.
32. Tyan YC, Wu HY, Lai WW, Su WC, Liao PC. Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry. J. Proteome Res. 2005; 4: 1274-86.
33. Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2001, 2: R4.
34. Miller JC, Zhou H, Kwekel J et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003; 3: 56-63.
35. Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc. Natl. Acad. Sci. USA 2003; 100: 9330-5.
36. Gulmann C, Espina V, Petricoin E 3rd et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin. Cancer Res. 2005; 11: 5847-55.
37. Boutell JM, Hart DJ, Godber BL, Kozlowski RZ, Blackburn JM. Functional protein microarrays for parallel characterisation of p53 mutants. Proteomics 2004; 4: 1950-8.
38. Braun P, Hu Y, Shen B et al. Proteome-scale purification of human proteins from bacteria. Proc. Natl. Acad. Sci. USA 2002; 99: 2654-9.
39. Ramachandran N, Hainsworth E, Bhullar B et al. Self-assembling protein microarrays. Science 2004; 305: 86-90.
40. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431: 931-45.
41. Reid GE, McLuckey SA. 'Top down' protein characterization via tandem mass spectrometry. J. Mass Spectrom. 2002; 37: 663-75.
42. Frahm JL, Howard BE, Heber S, Muddiman DC. Accessible proteomics space and its implications for peak capacity for zero-, one- and two-dimensional separations coupled with FT-ICR and TOF mass spectrometry. J. Mass Spectrom. 2006; 41: 281-8.
43. Govorukhina NI, Reijmers TH, Nyangoma SO, van der Zee AG, Jansen RC, Bischoff R. Analysis of human serum by liquid chromatography-mass spectrometry: improved sample preparation and data analysis. J. Chromatogr. A 2006; 1120: 142-150.
44. Sun W, Wu S, Wang X, Zheng D, Gao Y. An analysis of protein abundance suppression in data dependent liquid chromatography and tandem mass spectrometry with tryptic peptide mixtures of five known proteins. Eur. J. Mass Spectrom. (Chichester, Eng) 2005; 11: 575-80.
45. Echan LA, Tang HY, Ali-Khan N, Lee K, Speicher DW. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 2005; 5: 3292-303.